Actively Recruiting
Phase 1 Study to Find Safe Dose of Zeaxanthin Alone or With Pembrolizumab for Patients With Advanced Solid Tumors
Led by Valley Health System · Updated on 2026-06-05
72
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and best dosing of an oral compound called zeaxanthin in patients with advanced metastatic solid tumors or unresectable stage 3 cancers. The study aims to find the highest daily dose of zeaxanthin that can be safely taken, assess its side effects, and determine dosing for future cancer trials. Effects on tumor growth will also be observed as a secondary goal. Participants will receive zeaxanthin alone or combined with pembrolizumab, an intravenous cancer drug given every 42 days. The study uses a stepwise dosing approach, starting with 2 mg per kilogram of body weight and increasing up to 8 mgkg if tolerated. If a dose is unsafe, a new group will be treated at a midpoint dose. Zeaxanthin is supplied in 50 mg capsules, with doses rounded to the nearest capsule. During the trial, participants will be monitored for side effects within 28 days for zeaxanthin alone and within 42 days when combined with pembrolizumab, with treatment periods lasting up to 20 weeks per dose group. Researchers will track tumor response, duration of response, disease control rates, and progression-free survival for up to 36 months. Blood samples will be taken at specific intervals to measure zeaxanthin levels. The study will continue through March 2028.
CONDITIONS
Brief Title
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Research Team
S
Sequoia Young, MS
R
Robyn Chicherchia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here